Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

chemicalbilly/E+ via Getty Images Abeona Therapeutics Inc. (NASDAQ:ABEO) dropped by more than half on Tuesday after the company received a Complete Response Letter from the FDA in response to the Company’s Biologics License Application for pz-cel. In one day, ABEO erased nearly a year's worth of gains that had been building on positive speculation that pz-cel would gain approval at next month's PDUFA. Those hopes were dashed as the FDA identified manufacturing issues that the company must take the next  ...